Table 2.
Clinical summary for pSS fatigue groups showing mean±SD for key demographics, haematological and clinical variables
| Variable | Minimal | Mild | Moderate | Severe | p Value |
|---|---|---|---|---|---|
| Age (years) | 62±10 | 58±14 | 60±12 | 59±13 | ns |
| Disease duration (years) | 5.5±5.8 | 6.1±5.2 | 7.5±6.2 | 9.1±7.3 | ns |
| Symptom duration (years) | 13±10 | 13±11 | 14±11 | 16±13 | ns |
| BMI (kg/m2) | 25±4.4 | 26±4.2 | 26±6.3 | 28±7.2 | ns |
| % Anti-Ro/La positive | 91.67 | 95.45 | 83.08 | 92.31 | ns |
| % Not taking any immune-altering medications | 67 | 59 | 52 | 50 | ns |
| % On hydroxychloroquine | 17 | 34 | 37 | 34 | ns |
| % On prednisolone | 8 | 5 | 6 | 12 | ns |
| % On ‘other’ immune-altering medications | 8 | 2 | 5 | 4 | ns |
| ESSDAI | 5.4±5.7 | 7.6±8.2 | 5.9±5.2 | 7.2±6.1 | ns |
| ESSPRI | 2.9±1.3 | 4.3±1.4 | 6.6±1.4 | 8.3±1.1 | ≤0.0001 |
| ESSPRI pain | 1.4±1.5 | 3.2±2.5 | 5.4±2.6 | 8±1.6 | ≤0.0001 |
| ESSPRI dryness | 5.6±2.7 | 5.5±2.2 | 6.9±2.6 | 8.1±2 | ≤0.0001 |
| EULAR SS | 5.3±2.5 | 5.6±2.5 | 6.8±2.5 | 7.8±2 | 0.0004 |
| HADS anxiety (0–21) | 3.7±2.4 | 6.5±3.5 | 8.6±4.4 | 12±4.9 | ≤0.0001 |
| HADS depression (0–21) | 2±1.9 | 4±2.8 | 7.4±3.5 | 11±2.9 | ≤0.0001 |
| Hb (g/dL) | 12±1.6 | 13±1.2 | 13±1.2 | 13±1.1 | ns |
| WCC (×109/L) | 5.5±1.4 | 5.2±1.5 | 5.2±2.0 | 6.3±2.7 | ns |
| Neutrophil (×109/L) | 3.5±1.1 | 3.3±1.3 | 3.2±1.5 | 3.7±2 | ns |
| Lymphocyte (×109/L) | 1.4±0.6 | 1.3±0.5 | 1.4±0.6 | 1.9±0.9 | 0.002 |
| ESR (mm/h) | 39±26 | 33±25 | 27±24 | 24±20 | ns |
| CRP (mg/L) | 6.4±5 | 5±4.1 | 5.2±5.9 | 6.7±5.8 | ns |
| IgG (mg/dL) | 20±8.8 | 18±8 | 15±6.5 | 15±4.2 | 0.008 |
BMI, body mass index; CRP, C-reactive protein; ESSDAI, EULAR Sjögren's Syndrome Disease Activity Index; ESR, erythrocyte sedimentation rate; ESSPRI, EULAR Sjögren's Syndrome Patient Reported Index; EULAR SS, EULAR Sicca Score; HADS, Hospital Anxiety and Depression Score; Hb, haemoglobin; pSS, primary Sjögren's syndrome; WCC, white cell count.